Evidentiary standards for new or supplementary cancer therapeutic indication approvals by the FDA are consistent with off-label indication inclusions on Medicare-referenced compendia.
Nicholas S. Downing, MD
Advertisement
Articles by Nicholas S. Downing, MD
Advertisement
Latest Updated Articles
- Cancer Therapeutic Clinical Trials Supporting FDA Approval and Compendia Inclusion
Published: July 28th 2017 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Operationalizing Epcoritamab-GemOx in Practice: A Focus on EPCORE NHL-2
2
Under Pressure: A Brief Overview of the Updated Hypertension Guidelines
3
Biosimilar Stivant Shows Noninferior Efficacy and Comparable Safety to Reference Bevacizumab
4
Current and Emerging BCMAxCD3 Bispecifics
5
